Satellos Bioscience Inc.
MSLE
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies for degenerative muscle diseases. Satellos Bioscience Inc. works in regenerative medicine, using its proprietary MyoReGenX platform to study muscle stem cell biology and identify approaches that may restore the body’s natural ability to repair muscle. The company’s current efforts center on small-molecule therapeutics, including programs aimed at Duchenne muscular dystrophy and other serious neuromuscular disorders. Its work is directed at improving treatment options in a field with significant unmet medical need, where muscle regeneration and function are central to patient care. Based in Toronto, Satellos Bioscience Inc. operates as a research-driven drug development company within the broader biotechnology and healthcare markets.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$35M
▼ -27.0% YoY
Op. Margin
–
ROIC
-55.69%
▼ -23.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -35.6% YoY
Op. Cash Flow (TTM)
-$29M
▼ -35.6% YoY
Net Debt
-$28M
Net Cash Position
Cash & Equiv.
$28M
Continue Research
Peers
Biotechnology · Pick stocks to compare with MSLE
Satellos Bioscience (MSLE) in three numbers
Questions about Satellos Bioscience
Is Satellos Bioscience a high-quality business?
Satellos Bioscience scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$28M, and its weakest is return on capital at -55.7%. The Quality tab shows every check against its target.
Does Satellos Bioscience (MSLE) pay a dividend?
No. Satellos Bioscience (MSLE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MSLE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.